Advances in AAV for Gene Therapy
&
Therapeutic Protein Production
In light of ongoing developments with the COVID-19 pandemic, Bioproduction Summit 2020, San Francisco will now be delivered in a 100% virtual format. Registration for the virtual conference is now open. Preliminary agenda can be viewed here and stay tuned for the final agenda!
Advances in AAV for Gene Therapy
&
Therapeutic Protein Production
Director of the Berkeley Stem Cell Center,
UC Berkeley
Co-founder, Executive Managing Director,
The Discovery Labs
Assistant Professor of Viral Gene Therapy,
UCSF
CEO and Cofounder,
Dyno Therapeutics
Chief Scientific Officer,
RegenXBIO
Vice President,
Ultragenyx
Founder & Managing Director ,
August Co
Scientist Gene Therapy,
Biogen
Associate Director & Associate Professor,
Powell Gene Therapy Center
Bioproduction Summit brings together industry leaders and biotech experts to discuss most challenging issues, ranging from achieving high productivities to scalable platform processes. In addition to popular therapeutic protein production theme, we will feature topics on tackling current manufacturing challenges in the exponentially growing field of AAV Gene and Cell Therapy. Lessons learned from the CHO cell culture will immensely help the field of AAV. Thus bringing experts from these two fields together will accelerate pace of innovations in the coming years.
This conference provides an excellent venue for start ups as well as established biotech organization to collaborate, network and exhibit latest innovations in the field. We are delighted to invite you to present your latest research and technologies as speaker, poster presenter and exhibitor. For more details contact us
Senior Manager, Cell Culture GE Healthcare
William G Whitford is Sr. Manager, Cell Culture, GE Healthcare in Logan, UT with over 20 years experience in biotechnology product and process development. He joined the company 12 years ago as a team leader in R&D developing products supporting biomass expansion, protein expression and virus secretion in mammalian and invertebrate cell lines. Products he has commercialized include, defined and animal product-free hybridoma media, fed-batch supplements, and aqueous lipid dispersions. An invited lecturer at international conferences, he has published over 250 articles, book chapters and patents in a number of fields in the bioproduction arena. He now enjoys such industry activities as serving on the editorial advisory board for BioProcess International.
Process Science Manager, Thermo Fisher Scientific
Doan Tran is a Process Science Manager, Thermo Fisher Scientific, responsible for technical engagement with customers to insure they gain maximum benefit from Gibco catalog or custom Bioproduction cell culture products. Her current role involves support of cell line development, process development, media development and technical operations consultation in cell culture.
Vice President, Technical applications, Maxcyte Inc.
James Brady, Ph.D., is Vice President of Tehcnical Applications and Customer Support at Maxcyte Inc., where he has worked since 2004. Prior to joining Maxcyte, Dr. Brady was a senior scientist at Genetic Therapy Inc. ( a Novartis subsidiary) and a group leader at MetaMorphix, Inc.
